Leadership · from 2024 990-PF
Kelsey Martin
PRESIDENT/MANAGER
David Spergel
CHAIRPERSON/MANAGER
Euan Robertson
VICE PRESIDENT
Marlow Kee
TREASURER/MANAGER
Marion Greenup
SECRETARY (THRU 06/2023)
John Spiro
PRESIDENT/MANAGER (THRU 10/31/2021)
Marilyn H Simons
CHAIRPERSON/MANAGER (THRU 06/2021)
Louis F Reichardt
PRESIDENT/MANAGER (THRU 09/2020)
Source: IRS Form 990-PF, Part VII. Officers, directors, and trustees as reported by the foundation.
Recent grants · most recent filings first
The Children's Hospital of Philadelphia Research Institute
COMPUTER VISION BASED PHENOTYPING OF 16P11.2 ARBACLOFEN DOUBLE BLIND PLACEBO CONTROLLED STUDY.
PA · TY 2024
$200K
University of Washington
ELECTROPHYSIOLOGICAL INDICES OF NEURAL FUNCTION ASSOC. WITH ARBACLOFEN ADMIN. IN 16P11.2
WA · TY 2021
$45K
University of Washington
ELECTROPHYSIOLOGICAL INDICES OF NEURAL FUNCTION ASSOC. WITH ARBACLOFEN ADMIN. IN 16P11.2
WA · TY 2020
$125K
The Children's Hospital of Philadelphia Research Institute
COMPUTER VISION BASED PHENOTYPING OF 16P11.2 ARBACLOFEN DOUBLE BLIND PLACEBO CONTROLLED STUDY.
PA · TY 2020
$108K
University of Washington
Electrophysiological Indices of Neural Function Associated with Arbaclofen Administration in 16p11.2
WA · TY 2019
$80K
The Childrens Hospital of Philadelphia Research
Computer Vision Based Digital Phenotyping of 16p11.2 Arbaclofen Double Blind Placebo Controlled Study
PA · TY 2019
$73K
The Childrens Hospital of Philadelphia
MEG/MRS Dose Response Study of STX209 in ASD
PA · TY 2018
$150K
King's College London
GABAb in ASD. A high dose Arbaclofen fMRI and visual processing study.
TY 2018
$75K
Massachusetts Institute of Technology
Advancing a Biomarker of Reduced GABAergic Action in the Autistic Brain
MA · TY 2018
$39K
Institut de Genetique Et de Biologie Moleculaire
R-Baclo2: Retesting the Arbaclofen treatment on the Del(7Sult1a1-Spn)6Yah 16p11.2 deletion model
TY 2018
$18K
Massachusetts Institute of Technology
Advancing a Biomarker of Reduced GABAergic Action in the Autistic Brain
MA · TY 2017
$230K
The Childrens Hospital of Philadelphia
MEG/MRS Dose Response Study of STX209 in ASD
PA · TY 2017
$150K
The Regents of the University of California
Preclinical evaluation of therapeutic efficacy of r-baclofen in reversing behavioral deficits in 16p11.2 deletion mice
CA · TY 2017
$88K
The Trustees of the University of Pennsylvania
Assessment of Arbaclofen treatment on habituation, cognition and repetitive motor behaviors in a mouse model of 16p 11.2…
PA · TY 2017
$86K
Institut de Genetique Et de Biologie Moleculaire
R-Baclo2: Retesting the Arbaclofen treatment on the Del(7Sult1a1-Spn)6Yah 16p11.2 deletion model
TY 2017
$78K
King's College London
GABAb in ASD. A high dose Arbaclofen fMRI and visual processing study.
TY 2017
$75K
John Hopkins University School of Medicine
Development of radiotracers for PET imaging of GABA-B receptors in non-human primates
MD · TY 2017
$74K
Harvard Medical School
Using Motion Sequencing to Assess Behavioral Effects of Arbaclofen
MA · TY 2017
$60K
Kaiser Foundation Research Institute
ASD Family Biobank Program
CA · TY 2015
$545K
Foundation for the National Institutes of Health
Consortium on Biomarker and Outcome Measures of Social Impairment for Use in Clinical Trials in Autism Spectrum Disorder
MD · TY 2015
$500K
Weill Medical College of Cornell University
Advancing a Standardized Research Protocol to Study Treatment Effects in Individuals with Autism Spectrum Disorder
NY · TY 2015
$157K
Weill Medical College of Cornell University
To fund studies in Autism Spectrum Disorders
NY · TY 2014
$157K
Source: IRS Form 990-PF, Part XV. Up to 50 most recent grants shown.